Tresiba (insulin degludec) and Lantus (insulin glargine) are Food and Drug Administration (FDA)-approved synthetic insulins for glycemic control (blood sugar levels) in people with type 1 or type ...

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Study participants who received efsitora achieved a non-inferior reduction of A1C (a measure of average blood sugar) that was similar to daily shots of Lantus and Tresiba. The safety and ...

Tresiba also appears to offer greater dosing flexibility and less risk of hypoglycemia than Sanofi's top-selling Lantus. This should help Novo continue to gain share despite biosimilar Lantus ...